Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


12. January 2021 | 10:28 CET

CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!

  • Healthcare
Photo credits: pixabay.com

The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.

time to read: 2 minutes by Carsten Mainitz


 

Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author


CUREVAC NV - Approval expected by the beginning of the second quarter

While vaccines from BioNTech and Moderna are now being administered in Germany, Tübingen-based CureVac takes further necessary steps towards the product's approval. Yesterday, CureVac reported that preclinical data from the Covid-19 vaccine candidate CVnCoV confirmed the induction of a distinct immune response in non-human primates. In the study, the vaccine was tested in rhesus macaques with two vaccinations within 28 days.

"The complete protection of the lungs of vaccinated animals demonstrates the potential of CVnCoV to protect humans from the devastating effects of the virus. We are very encouraged that CVnCoV is effective at a low dose. The amount is even lower than the dose we are currently testing with in the pivotal clinical trial," stated Dr. Mariola Fotin-Mleczek, Chief Technology Officer of the Company.

The Company plans to complete the final Phase 3 in the first quarter and expects approval no later than the second quarter's beginning. The advantage of the CureVac vaccine is that it can be stored at refrigerator temperature for three months. With the products currently available, these are only a few days or weeks. The Tübingen-based Company plans to sell 300 million doses of the vaccine in 2021. The EU has already ordered 225 million doses.

At a current share price of around USD 103, the Company is valued at EUR 14 billion market capitalization. Analyst estimates are that the Group will generate EUR 1.5 billion in sales in the current year and EUR 2.5 billion in 2022. If analysts are to be believed, the share is currently too expensive. On average, the experts' target price is USD 72. Stock exchange trades the future. We are curious.

Q&M DENTAL GROUP - facing a revaluation

Singapore-based Q&M Dental Group is a leading private dental provider in Asia. The Group owns the largest network of 114 practices in the island nation and operates in Malaysia and China. Q&M was founded in 1996 and has established itself as a renowned, high-quality brand.

In addition to this bread-and-butter business, Q&M is building a new division that should lead to the Company's revaluation. In September, it was announced that the Ministry of Health licensed its 51% subsidiary, Acumen Diagnostics Pte, to offer clinical laboratory testing for SARS CoV-2 RNA. Q&M expects strong growth with very high margins. Another new revenue stream is the sale of a proprietary Corona test. It has already been sold to Malaysia and Indonesia. We estimate each order to be worth 5 million units or more. More countries will likely turn to Q&M's products.

When converted, the profitable Company is valued at EUR 280 million. Given the considerable potential in the "Corona business," a revaluation of the Company should occur soon.

MODERNA INC - Vaccine available in Germany since yesterday

A second Corona vaccine has been available in Germany since yesterday. The US manufacturer Moderna delivered 63,600 vaccine doses to a central depot in the district of Osnabrück. Moderna has long focused on the discovery and development of messenger RNA (mRNA) based drugs.

While BioNTech's vaccine must be stored and transported at minus 70 degrees, Moderna's vaccine doses can be stored at just minus 20 degrees and have a much longer shelf life at refrigerator temperatures than its competitor.

At the current USD 118 per share, the Massachusetts-based biotechnology Company is valued at USD 45 billion. The average price target of analysts following the stock is USD 135.


Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

17. March 2021 | 07:25 CET | by Nico Popp

Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

  • Healthcare

The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

Read

19. January 2021 | 10:50 CET | by Nico Popp

Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?

  • Healthcare

We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.

Read

18. June 2020 | 08:40 CET | by Mario Hose

BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?

  • Healthcare

Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.

Read